<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00520767</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000555016</org_study_id>
    <secondary_id>P30CA022453</secondary_id>
    <secondary_id>WSU-2006-132</secondary_id>
    <secondary_id>MILLENNIUM-WSU-2006-132</secondary_id>
    <secondary_id>WSU-HIC-060907M1F</secondary_id>
    <nct_id>NCT00520767</nct_id>
  </id_info>
  <brief_title>Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease</brief_title>
  <official_title>A Multicenter Phase II Trial of Bortezomib (Velcade), Melphalan, and Dexamethasone (V-MD) in Patients With Symptomatic AL-Amyloidosis or Light Chain Deposition Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving bortezomib together with melphalan and dexamethasone may be an effective
      treatment for primary amyloidosis and light chain deposition disease.

      PURPOSE: This phase II trial is studying how well giving bortezomib together with melphalan
      and dexamethasone works in treating patients with primary amyloidosis or light chain
      deposition disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the complete hematologic response rate at 12 months.

      Secondary

        -  Determine the overall hematologic response rate.

        -  Determine the organ response rate.

        -  Determine time to treatment failure.

        -  Assess toxicity of the regimen, in terms of incidence and severity of treatment-emergent
           peripheral neuropathy and quality of life.

        -  Determine the overall survival.

      OUTLINE: This is a multicenter study.

      Patients receive oral melphalan on days 1-4, bortezomib IV on days 1, 8, 15, and 22, and
      dexamethasone orally or IV on days 1, 2, 8, 9, 15, 16, 22, and 23. Treatment repeats every
      4-6 weeks for up to 20 courses in the absence of disease progression or unacceptable
      toxicity.

      Blood, urine, and bone marrow aspirates are collected at baseline and periodically after
      treatment to permit the correlation of clinical results with measured molecular events. A
      single baseline peripheral blood DNA sample is collected for future association studies
      linking disease onset, progression, and response to administered therapy with single
      nucleotide polymorphisms. Blood plasma and urine samples are evaluated for proteomic markers
      associated with disease progression and therapeutic response. Peripheral blood RNA samples
      are evaluated for transcriptional response to treatment of peripheral blood lymphocytes. Bone
      marrow aspirates are collected to extract plasma cells by flow cytometry for gene expression
      profiling.

      Quality of life is assessed at the beginning of each course.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Hematologic Response</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Day 1 of Each Cycle and every 12 weeks after last treatment cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Failure</measure>
    <time_frame>Day 1 of Each Cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life From Baseline as Assessed by the Functional Assessment of Cancer Therapy-Neurotoxicity Questionnaire.</measure>
    <time_frame>At the start of each cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ Response Rate (OrR)</measure>
    <time_frame>Beginning of cycles 4, 8, 12, 16 and 20, at follow up and end of study.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity, Including Neurotoxicity</measure>
    <time_frame>Day 1 of Each Cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Hematologic Response Rate (OHR)</measure>
    <time_frame>Beginning of cycles 4, 8, 12, 16 and 20, at follow up and end of study.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Primary Systemic Amyloidosis</condition>
  <condition>Light Chain Deposition Disease</condition>
  <arm_group>
    <arm_group_label>Melphalan, Dexamethasone, Bortezomib,</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bortezomib 1.3 mg/m2 days 1, 8, 15, 22; Dexamethasone 40 mg/d days 1, 2, 8, 9, 15, 16, 22, 23; Melphalan 9 mg/m2/day days 1-4</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
    <description>Bortezomib 1.3 mg/m2 days 1, 8, 15, 22</description>
    <arm_group_label>Melphalan, Dexamethasone, Bortezomib,</arm_group_label>
    <other_name>Velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>Dexamethasone 40 mg/d days 1, 2, 8, 9, 15, 16, 22, 23</description>
    <arm_group_label>Melphalan, Dexamethasone, Bortezomib,</arm_group_label>
    <other_name>Dexasone</other_name>
    <other_name>Decadron</other_name>
    <other_name>Diodex</other_name>
    <other_name>Hexadrol</other_name>
    <other_name>Maxidex</other_name>
    <other_name>Dexamethasone Sodium Phosphate</other_name>
    <other_name>Dexamethasone Acetate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <description>Melphalan 9 mg/m2/day days 1-4</description>
    <arm_group_label>Melphalan, Dexamethasone, Bortezomib,</arm_group_label>
    <other_name>Alkeran®</other_name>
    <other_name>L-PAM</other_name>
    <other_name>L-Sarcolysin</other_name>
    <other_name>Phenylalanine Mustard</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>microarray analysis</intervention_name>
    <description>≤28 days prior to enrollment</description>
    <arm_group_label>Melphalan, Dexamethasone, Bortezomib,</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>flow cytometry</intervention_name>
    <description>Day 1 of cycles 6, 12, 18 and at end of study.</description>
    <arm_group_label>Melphalan, Dexamethasone, Bortezomib,</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>≤28 days prior to enrollment</description>
    <arm_group_label>Melphalan, Dexamethasone, Bortezomib,</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <description>Start of each cycle</description>
    <arm_group_label>Melphalan, Dexamethasone, Bortezomib,</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Biopsy-proven diagnosis of 1 of the following:

               -  Primary systemic amyloidosis

                    -  Histochemical diagnosis of amyloidosis determined by polarizing microscopy
                       of green bi-refringent material in Congo red-stained tissue specimens or
                       characteristic electron microscopy appearance

               -  Light chain deposition disease

          -  Measurable disease as defined by one or more of the following:

               -  Serum monoclonal protein ≥ 0.5 g/dL by serum electrophoresis

               -  Urine monoclonal protein &gt; 200 mg/tv in a 24 hr urine electrophoresis

               -  Serum immunoglobulin free-light chain ≥ 10 mg/dL AND abnormal serum
                  immunoglobulin kappa lambda free light chain ratio

          -  Must meet 1 of the following criteria:

               -  Clonal population of plasma cells in the bone marrow (≤ 30%)

               -  Immunohistochemical stain with anti-light chain anti-sera of amyloid fibrils

          -  Must not meet the following diagnostic criteria for symptomatic* multiple myeloma:

               -  Lytic lesions on skeletal survey

               -  Plasmacytoma

               -  Increase in bone marrow plasma cells ≥ 30% NOTE: *Patients who meet the
                  International Myeloma Working Group definition of symptomatic multiple myeloma
                  with symptoms attributable only to associated amyloidosis and who do not
                  otherwise meet the criteria for diagnosis of smoldering myeloma are potentially
                  eligible upon approval of the principal investigator.

          -  If not previously treated, patient is either not a candidate for autologous stem cell
             transplantation (ASCT) or has declined the option of ASCT

               -  Patients who have undergone prior ASCT and have subsequently progressed are
                  eligible, provided other eligibility criteria are met

          -  No secondary or familial amyloidosis

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-3

          -  Creatinine &lt; 5 mg/dL

          -  Bilirubin &lt; 2.5 times upper limit of normal (ULN)

          -  ALT and AST &lt; 3 times ULN

          -  Absolute neutrophil count ≥ 1,000/mm³

          -  Platelet count ≥ 80,000/mm³

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  Peripheral sensory neuropathy &lt; grade 3

          -  No myocardial infarction within the past 6 months

          -  No New York Heart Association class III or IV heart failure

          -  No uncontrolled angina

          -  No severe uncontrolled ventricular arrhythmias

          -  No EKG* evidence of acute ischemia or active conduction system abnormalities (not
             including 1st degree AV-block, Wenckebach type 2nd degree heart block, or left bundle
             branch block) NOTE: *Prior to study entry, any EKG screening abnormality must be
             documented by the investigator as not medically relevant; there is no lower limit of
             LVEF below which patients are excluded from participation

          -  No hypersensitivity to bortezomib, boron, or any of the other agents utilized in this
             study

          -  No serious concurrent illness (e.g., stroke) within the past 30 days

          -  No psychiatric illness likely to interfere with study participation

          -  No untreated HIV infection

               -  Patients with asymptomatic HIV infection on active antiretroviral therapy are
                  potentially eligible

          -  No diagnosis or treatment of another malignancy within the past 3 years, except
             completely resected basal cell or squamous cell carcinoma of the skin, an in situ
             malignancy, or low-risk prostate cancer after curative therapy

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No other investigational drugs within the past 14 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey A. Zonder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers/Rocky Mountain Blood &amp; Marrow Transplant Program</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University Cancer Research Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Josephine Ford Cancer Center at Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Institute at Providence Hospital - Southfield Campus</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Cancer Centers</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2007</study_first_submitted>
  <study_first_submitted_qc>August 24, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2007</study_first_posted>
  <results_first_submitted>March 18, 2015</results_first_submitted>
  <results_first_submitted_qc>March 18, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 30, 2015</results_first_posted>
  <last_update_submitted>April 5, 2017</last_update_submitted>
  <last_update_submitted_qc>April 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Barbara Ann Karmanos Cancer Institute</investigator_affiliation>
    <investigator_full_name>Jeffrey Zonder</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>primary systemic amyloidosis</keyword>
  <keyword>light chain deposition disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Melphalan, Dexamethasone, Bortezomib,</title>
          <description>Bortezomib 1.3 mg/m2 days 1, 8, 15, 22; Dexamethasone 40 mg/d days 1, 2, 8, 9, 15, 16, 22, 23; Melphalan 9 mg/m2/day days 1-4
bortezomib: Bortezomib 1.3 mg/m2 days 1, 8, 15, 22
dexamethasone: Dexamethasone 40 mg/d days 1, 2, 8, 9, 15, 16, 22, 23
melphalan: Melphalan 9 mg/m2/day days 1-4
microarray analysis: ≤28 days prior to enrollment
flow cytometry: Day 1 of cycles 6, 12, 18 and at end of study.
laboratory biomarker analysis: ≤28 days prior to enrollment
quality-of-life assessment: Start of each cycle</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Melphalan, Dexamethasone, Bortezomib,</title>
          <description>Bortezomib 1.3 mg/m2 days 1, 8, 15, 22; Dexamethasone 40 mg/d days 1, 2, 8, 9, 15, 16, 22, 23; Melphalan 9 mg/m2/day days 1-4
bortezomib: Bortezomib 1.3 mg/m2 days 1, 8, 15, 22
dexamethasone: Dexamethasone 40 mg/d days 1, 2, 8, 9, 15, 16, 22, 23
melphalan: Melphalan 9 mg/m2/day days 1-4
microarray analysis: ≤28 days prior to enrollment
flow cytometry: Day 1 of cycles 6, 12, 18 and at end of study.
laboratory biomarker analysis: ≤28 days prior to enrollment
quality-of-life assessment: Start of each cycle</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" lower_limit="47" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Complete Hematologic Response</title>
        <time_frame>Up to 12 months</time_frame>
        <population>Individuals evaluable for response</population>
        <group_list>
          <group group_id="O1">
            <title>Melphalan, Dexamethasone, Bortezomib,</title>
            <description>Bortezomib 1.3 mg/m2 days 1, 8, 15, 22; Dexamethasone 40 mg/d days 1, 2, 8, 9, 15, 16, 22, 23; Melphalan 9 mg/m2/day days 1-4
bortezomib: Bortezomib 1.3 mg/m2 days 1, 8, 15, 22
dexamethasone: Dexamethasone 40 mg/d days 1, 2, 8, 9, 15, 16, 22, 23
melphalan: Melphalan 9 mg/m2/day days 1-4
microarray analysis: ≤28 days prior to enrollment
flow cytometry: Day 1 of cycles 6, 12, 18 and at end of study.
laboratory biomarker analysis: ≤28 days prior to enrollment
quality-of-life assessment: Start of each cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Hematologic Response</title>
          <population>Individuals evaluable for response</population>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>individuals</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>individuals</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>Day 1 of Each Cycle and every 12 weeks after last treatment cycle</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Treatment Failure</title>
        <time_frame>Day 1 of Each Cycle</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life From Baseline as Assessed by the Functional Assessment of Cancer Therapy-Neurotoxicity Questionnaire.</title>
        <time_frame>At the start of each cycle</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Organ Response Rate (OrR)</title>
        <time_frame>Beginning of cycles 4, 8, 12, 16 and 20, at follow up and end of study.</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity, Including Neurotoxicity</title>
        <time_frame>Day 1 of Each Cycle</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Hematologic Response Rate (OHR)</title>
        <time_frame>Beginning of cycles 4, 8, 12, 16 and 20, at follow up and end of study.</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Melphalan, Dexamethasone, Bortezomib,</title>
          <description>Bortezomib 1.3 mg/m2 days 1, 8, 15, 22; Dexamethasone 40 mg/d days 1, 2, 8, 9, 15, 16, 22, 23; Melphalan 9 mg/m2/day days 1-4
bortezomib: Bortezomib 1.3 mg/m2 days 1, 8, 15, 22
dexamethasone: Dexamethasone 40 mg/d days 1, 2, 8, 9, 15, 16, 22, 23
melphalan: Melphalan 9 mg/m2/day days 1-4
microarray analysis: ≤28 days prior to enrollment
flow cytometry: Day 1 of cycles 6, 12, 18 and at end of study.
laboratory biomarker analysis: ≤28 days prior to enrollment
quality-of-life assessment: Start of each cycle</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>thrombocytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Congestive Heart Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Ventricular Arrhythmia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>cardiac Arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pain-chest wall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection with Normal ANC-Lung (pneumonia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Infection with Normal ANC-Catheter related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Infection with Normal ANC-Skin (cellulitis)-shingles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pain-Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental Status Change</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Mix of previously treated &amp; newly diagnosed pts (populations which may have different prognoses), plus the relatively small trial size limit conclusions one can draw re: relative efficacy of MDV (vs CyBorD or Mel-Dex, for example)</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jeffrey Zonder, M.D.</name_or_title>
      <organization>Barbara Ann Karmanos Cancer Institute</organization>
      <phone>313-576-8732</phone>
      <email>zonderj@karmanos.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

